Navigation Links
TECNALIA investigates advanced biomaterials to make more reliable and hardwearing medical implants
Date:11/12/2008

The TECNALIA Technological Corporation is taking part in the Cnit Intelimplant project, the goal of which is to develop advanced biomaterials based on innovative technologies (microtechnologies, nanotechnologies, tissue and surface engineering) for the manufacture of a new generation of implants which have greater durability and reliability, need less recuperation time and that provide data on their state and progress.

The Cnit Intelimplant project (Development of Advanced Biomaterials for a New Generation of Implants), led by the Biotechnology Institute (BTI), was one of the 16 projects approved by the Centre for Industrial Technological Development (CDTI) for the third CNIT programme announcement or call, within the Spanish Government INGENIO 2010 initiative.

The end goal of the project is the development of novel biomaterials which enable an extension of the functions of the implant throughout the whole life of the patient, in such a way that repeat surgical operations are avoided; the reliability and the integration of the implants are enhanced and tissue rejection avoided; the recuperation times for patients are significantly cut and the implants are operational in a minimum time; the state and progress of the implant monitored, both in the short term and in the long term after the surgical operation; the new materials will indicate any anomaly and enable the application of preventative therapies; and finally, they will simplify surgical practice, progressing to minimally invasive surgery and the automation of stages during an operation.

The project will be undertaken by a consortium made up of 15 companies, including state-of-the-art Spanish enterprises in the field of implants, BTI Biotechnology Institute, SURGIVAL, LAFITT, SOCINSER and IHT, as well as the most important ones in the value chain of their manufacture: KERAMAT, Laboratories INIBSA, BIOKER Research, METAL-ESTALKI, BIOVAC, DMP, i2m-DESIGN, ANLISIS & SIMULACIN (AyS), IHS WEIGLING and GEM-IMAGING.

The Intelimplant project involves groups belonging to 16 public and private research bodies: TECNALIA, the Institute of Biomechanics of Valencia-IBV, the Institute of Polymers Science and Technology (ICTP-CSIC), the University of Len, the University of Vigo, the University of Mlaga, the National Microelectronics Centre (CNM-CSIC), the Institute for Corpuscular Physics (IFIC-CSIC), the Institute of Ceramica Galicia, the Polytechnic University of Catalunya (UPC), PRODINTEC, INCAR, ICMM-CSIC, the University of Barcelona, the Bosch i Gimpera Foundation and the Chemical Institute of Sarri (IQS).

Carrying out this project will also enable fomenting synergies and reducing project development times through drawing up a joint-working framework between the various multidisciplinary players within the Science-Technology-Enterprise network. These players have knowledge and experience that complement each other and which are present throughout the whole value chain of the sector and, as a consequence, will give rise to enhanced competitiveness amongst the participating companies, thus reducing excessive external dependence, readdressing the unfavourable situation of our country as regards the transfer of research results by OPIs and CITs to companies in this field of advanced biomaterials, and improving the scientific-technical level of the enterprises taking part in the project. All this with the target of being in a more advantageous position to participate in international programmes of cooperation in scientific research and technological development, such as the FP VII.


'/>"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. TECNALIA leads five projects within the VII Framework Program
2. Queens marine biologist investigates aliens beneath the waves
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. Embryonic stem cell strategy advanced with UCSF finding
5. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
6. $1.1 million NSF grant to fund research in advanced light microscopy at UCLA
7. CSIC and UAB will build the most advanced superconductor cable for electricity network
8. Research at Argonnes Advanced Photon Source reveals structure and behavior of collagen
9. Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
10. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
11. Combining advanced medical and information technologies offers pathway to lower health care costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the ... for triple negative breast cancer (TNBC), announced today their completion ... program. The YEi Start in France ... grow their business in France and ... to complete an intensive one week immersion in ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
Breaking Biology Technology: